Literature DB >> 12559848

Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.

Toshika Okumiya1, Hitoshi Sakuraba, Ryoichi Kase, Tetsuro Sugiura.   

Abstract

G(M1)-gangliosidosis and Morquio B disease are distinct in clinical and biochemical features, but both disorders are caused by genetic defects of the same enzyme, acid beta-galactosidase (beta-Gal). We analyzed the kinetic properties of mutant beta-Gals from patients with G(M1)-gangliosidosis and Morquio B disease to examine the clinical and biochemical differences between both disorders. Five skin fibroblast lines from patients with G(M1)-gangliosidosis (2 cases; R201C/R201C and I51T/I51T), Morquio B disease (2 cases; W273L/W273L and Y83H/R482C), and galactosialidosis (1 case; Y395C/S90L) were used as enzyme sources. Residual enzyme activity in the cells was subjected to kinetic analysis. Substrate analogs including Galbeta1-3GalNAc, as an analog for G(M1)-ganglioside, and Galbeta1-4GlcNAc, as an analog for keratan sulfate, were used to determine IC(50) and K(i) for beta-Gals with an artificial substrate (4-methylumbelliferyl beta-D-galactopyranoside). Enzymatic assay method was established to examine the hydrolytic activity with the mutant beta-Gal for the substrate analogs. The mutant beta-Gal activities were inhibited by Galbeta1-3GalNAc and Galbeta1-4GlcNAc in a concentration-dependent manner. Remarkable increase in IC(50) ratio and K(i) ratio (Galbeta1-4GlcNAc/Galbeta1-3GalNAc) was observed in Morquio B disease. Relative hydrolytic activity (Galbeta1-4GlcNAc/Galbeta1-3GalNAc) was markedly decreased in Morquio B disease as compared with other subjects; controls (means+/-SD, n=4), 1.00+/-0.02; galactosialidosis, 1.03; G(M1)-gangliosidosis, 1.15 and 1.00; and Morquio B disease, 0.27 and 0.32. The mutant beta-Gals from the patients with Morquio B disease exhibited lower affinity and lower hydrolytic activity toward Galbeta1-4GlcNAc rather than Galbeta1-3GalNAc. These findings suggest that imbalanced substrate specificity of the mutant beta-Gals induces predominant accumulation of keratan sulfate and a rationale for performing differential diagnostic analysis for both disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559848     DOI: 10.1016/s1096-7192(02)00199-3

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  The skeletal phenotype of intermediate GM1 gangliosidosis: Clinical, radiographic and densitometric features, and implications for clinical monitoring and intervention.

Authors:  Carlos R Ferreira; Debra S Regier; Robin Yoon; Kristen S Pan; Jean M Johnston; Sandra Yang; Jürgen W Spranger; Cynthia J Tifft
Journal:  Bone       Date:  2019-11-06       Impact factor: 4.398

2.  Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.

Authors:  Katrin M Fantur; Tanja M Wrodnigg; Arnold E Stütz; Bettina M Pabst; Eduard Paschke
Journal:  J Inherit Metab Dis       Date:  2011-10-28       Impact factor: 4.982

3.  Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.

Authors:  Umeharu Ohto; Kimihito Usui; Toshinari Ochi; Kenjiro Yuki; Yoshinori Satow; Toshiyuki Shimizu
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

4.  Rare Diseases in Glycosphingolipid Metabolism.

Authors:  Hongwen Zhou; Zhoulu Wu; Yiwen Wang; Qinyi Wu; Moran Hu; Shuai Ma; Min Zhou; Yan Sun; Baowen Yu; Jingya Ye; Wanzi Jiang; Zhenzhen Fu; Yingyun Gong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Beta-galactosidase deficiencies and novel GLB1 mutations in three Chinese patients with Morquio B disease or GM1 gangliosidosis.

Authors:  Hong-Lin Lei; Jun Ye; Wen-Juan Qiu; Hui-Wen Zhang; Lian-Shu Han; Yu Wang; Xue-Fan Gu
Journal:  World J Pediatr       Date:  2012-11-15       Impact factor: 2.764

Review 6.  Ganglioside biochemistry.

Authors:  Thomas Kolter
Journal:  ISRN Biochem       Date:  2012-12-19

7.  Morquio B patient/caregiver survey: First insight into the natural course of a rare GLB1 related condition.

Authors:  Maria Bleier; Nataliya Yuskiv; Tina Priest; Marioara Angela Moisa Popurs; Sylvia Stockler-Ipsiroglu
Journal:  Mol Genet Metab Rep       Date:  2018-07-20

8.  Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex.

Authors:  Iman S Abumansour; Nataliya Yuskiv; Eduard Paschke; Sylvia Stockler-Ipsiroglu
Journal:  JIMD Rep       Date:  2019-11-28

9.  Characterization of glycan substrates accumulating in GM1 Gangliosidosis.

Authors:  Roger Lawrence; Jeremy L Van Vleet; Linley Mangini; Adam Harris; Nathan Martin; Wyatt Clark; Sanjay Chandriani; Jonathan H LeBowitz; Roberto Giugliani; Alessandra d'Azzo; Gouri Yogalingam; Brett E Crawford
Journal:  Mol Genet Metab Rep       Date:  2019-11-03

10.  Morquio-like dysostosis multiplex presenting with neuronopathic features is a distinct GLB1-related phenotype.

Authors:  Sylvia Stockler-Ipsiroglu; Nahid Yazdanpanah; Mojgan Yazdanpanah; Marioara Moisa Popurs; Nataliya Yuskiv; Mara Lúcia Schmitz Ferreira Santos; Chong Ae Kim; Carolina Fischinger Moura de Souza; Charles Marques Lourenço; Carlos Eduardo Steiner; Andressa Federhen; Luciana Giugliani; Débora Maria Bastos Pereira; Luz Elena Durán-Carabali; Roberto Giugliani
Journal:  JIMD Rep       Date:  2021-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.